A free trading terminal you can open right now
Meaterm is a browser-based free trading terminal with a permanent free tier — no credit card, no install, no trial countdown. If you have been searching for a free Bloomberg alternative for everyday market research, this page is the honest version of that pitch: what is actually free, what Pro adds, and why the model works.
What’s actually free
Most “free stock terminal” offers are two-week trials with a card form in front of them. Meaterm’s free tier is neither: it needs no payment details, and it does not expire. Here is the inventory, plainly:
- Market dashboard — A cross-asset overview of stocks, crypto and FX the moment you open the terminal.
- Charts — Interactive charting with indicators and drawing tools, straight in the browser.
- Multi-list watchlists — Organise the symbols you follow into as many lists as your workflow needs.
- Market news — A running feed of market headlines to keep context around your charts.
- Screener basics — Filter the stock universe by core criteria to build a shortlist worth researching.
That is enough to run a real daily routine — scan the dashboard, work your watchlists, chart a setup, screen for new ideas. The full capability map is on the features page.
Free vs Pro: what €9.99/month adds
The free tier is genuinely usable on its own. Pro, from €9.99/month, is for going deeper — it unlocks the research layer that usually only exists inside institutional terminals:
- Macro intelligence — FRED-backed dashboards for rates, inflation, VIX and credit spreads.
- CFTC COT positioning — See how large speculators and commercials are positioned each week.
- Advanced screener — Deeper filters, including SEC-filing fundamentals and factor grades.
- AI market briefings — Generated summaries of what moved and why — a starting point, not advice.
- Research hub extras — Per-symbol depth: peers, financials, dividends, estimates and an earnings calendar.
Pro also carries the on-chain crypto analytics and Polymarket prediction-market signals that round out the cross-asset picture. Full plan details are on the pricing page — paid plans come with a 14-day trial, and you can cancel anytime.
Why the free tier exists
“Free” in this industry usually means you are the product — ads in the sidebar, or a broker quietly paying for your order flow. Meaterm’s model is simpler and worth stating outright: the free tier is funded by Pro subscriptions. That is the entire business.
There are no ads on the platform. And because Meaterm is analysis-only — it never executes trades or connects to a brokerage — there is no order flow to monetise in the first place. The incentive is plain: make the free trading terminal good enough that some users eventually want the deeper macro, COT and AI tooling in Pro. If you never upgrade, the free tier still works, indefinitely.
A free Bloomberg alternative? Where that’s fair — and where it isn’t
A Bloomberg Terminal runs roughly $2,000+ per month and earns it with real-time institutional data, execution and a chat network. Meaterm does not pretend to replace that: market data here is delayed or end-of-day, and there is no order routing. If you need tick data or Level 2, a free market terminal — any free market terminal — is the wrong tool.
Where the comparison is fair is the research layer. Advanced charting with 25+ indicators, macro dashboards, COT positioning, on-chain analytics, prediction-market signals and SEC-filing fundamentals in one place is a workflow that otherwise means an institutional terminal or a stack of separate subscriptions (TradingView’s paid tiers alone run about $15–60/month). See the full side-by-side on the compare page, the deeper breakdown on Bloomberg Terminal alternatives, or the broader guide to choosing a trading terminal. If Finviz is your current free screener, Meaterm vs Finviz compares the two free tiers directly. See a live example: NVDA analysis.
How to start in 30 seconds
- Open the terminal in your browser — there is nothing to install.
- Create a free account so your watchlists and layout persist. No card details are asked for.
- Pull up a symbol, build a watchlist, run the screener — you are researching.
Prefer an app? A desktop app and an installable mobile PWA are available too — same terminal, same account.
Free trading terminal — FAQ
Is the free trading terminal really free?
Yes. The free tier is permanent, not a trial: dashboard, charts, multi-list watchlists, market news and screener basics, with no credit card required to sign up. It is funded by Pro subscriptions, so there are no ads and nothing is sold behind your back.
Do I need to download or install anything?
No. Meaterm runs in your browser — open the terminal and start researching. If you prefer an app, there is an optional desktop app and an installable mobile PWA, but neither is required.
Is the market data real-time?
No — and we say so plainly. Equity and index data is delayed or end-of-day, and there is no tick-by-tick or Level 2 feed. Meaterm is built for research and analysis, not for millisecond execution, which is exactly why it can offer a free tier at all.
Can I place trades from the terminal?
No. Meaterm is analysis-only: it never places orders, holds funds or connects to a brokerage. You research here and execute on whichever broker or exchange you already use. Nothing on the platform is investment advice.
What does Pro add for €9.99/month?
Pro unlocks the deeper research layer: FRED-backed macro dashboards (rates, inflation, VIX, credit spreads), CFTC COT positioning data, advanced screener filters, AI market briefings, and extra depth in the per-symbol research hub — peers, financials, dividends and estimates.
Is Meaterm a free Bloomberg alternative?
For everyday cross-asset research, it plays in that space; as a literal replacement, no. A Bloomberg Terminal costs roughly $2,000+ per month and includes real-time institutional data and execution — Meaterm deliberately does neither. What it does cover, free to start, is the research layer: charting, macro, COT, on-chain analytics, prediction-market signals and fundamentals.
Meaterm is a research and analysis platform — not a brokerage, and not an investment adviser. Market data is delayed or end-of-day and may be revised by upstream providers. Nothing on this page or in the product is investment advice. Third-party pricing figures reflect publicly available information and may change; verify on each provider’s own site.